BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 27777101)

  • 1. Glycyrrhizin Ameliorates Fibrosis, Vasculopathy, and Inflammation in Animal Models of Systemic Sclerosis.
    Yamashita T; Asano Y; Taniguchi T; Nakamura K; Saigusa R; Miura S; Toyama T; Takahashi T; Ichimura Y; Yoshizaki A; Trojanowska M; Sato S
    J Invest Dermatol; 2017 Mar; 137(3):631-640. PubMed ID: 27777101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibrosis, vascular activation, and immune abnormalities resembling systemic sclerosis in bleomycin-treated Fli-1-haploinsufficient mice.
    Taniguchi T; Asano Y; Akamata K; Noda S; Takahashi T; Ichimura Y; Toyama T; Trojanowska M; Sato S
    Arthritis Rheumatol; 2015 Feb; 67(2):517-26. PubMed ID: 25385187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DZ2002 ameliorates fibrosis, inflammation, and vasculopathy in experimental systemic sclerosis models.
    Zhang Z; Wu Y; Wu B; Qi Q; Li H; Lu H; Fan C; Feng C; Zuo J; Niu L; Tang W
    Arthritis Res Ther; 2019 Dec; 21(1):290. PubMed ID: 31842999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A potential contribution of altered cathepsin L expression to the development of dermal fibrosis and vasculopathy in systemic sclerosis.
    Yamashita T; Asano Y; Taniguchi T; Nakamura K; Saigusa R; Takahashi T; Ichimura Y; Toyama T; Yoshizaki A; Miyagaki T; Sugaya M; Sato S
    Exp Dermatol; 2016 Apr; 25(4):287-92. PubMed ID: 26661692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tamibarotene Ameliorates Bleomycin-Induced Dermal Fibrosis by Modulating Phenotypes of Fibroblasts, Endothelial Cells, and Immune Cells.
    Toyama T; Asano Y; Akamata K; Noda S; Taniguchi T; Takahashi T; Ichimura Y; Shudo K; Sato S; Kadono T
    J Invest Dermatol; 2016 Feb; 136(2):387-398. PubMed ID: 26967475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic suppression of Fli1, a potential predisposing factor in the pathogenesis of systemic sclerosis.
    Asano Y
    Int J Biochem Cell Biol; 2015 Oct; 67():86-91. PubMed ID: 26055516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppressive Regulation by MFG-E8 of Latent Transforming Growth Factor β-Induced Fibrosis via Binding to αv Integrin: Significance in the Pathogenesis of Fibrosis in Systemic Sclerosis.
    Fujiwara C; Uehara A; Sekiguchi A; Uchiyama A; Yamazaki S; Ogino S; Yokoyama Y; Torii R; Hosoi M; Suto C; Tsunekawa K; Murakami M; Ishikawa O; Motegi SI
    Arthritis Rheumatol; 2019 Feb; 71(2):302-314. PubMed ID: 30175895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endothelial-to-mesenchymal transition contributes to endothelial dysfunction and dermal fibrosis in systemic sclerosis.
    Manetti M; Romano E; Rosa I; Guiducci S; Bellando-Randone S; De Paulis A; Ibba-Manneschi L; Matucci-Cerinic M
    Ann Rheum Dis; 2017 May; 76(5):924-934. PubMed ID: 28062404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bosentan reverses the pro-fibrotic phenotype of systemic sclerosis dermal fibroblasts via increasing DNA binding ability of transcription factor Fli1.
    Akamata K; Asano Y; Aozasa N; Noda S; Taniguchi T; Takahashi T; Ichimura Y; Toyama T; Sato S
    Arthritis Res Ther; 2014 Apr; 16(2):R86. PubMed ID: 24708674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The nuclear receptor constitutive androstane receptor/NR1I3 enhances the profibrotic effects of transforming growth factor β and contributes to the development of experimental dermal fibrosis.
    Avouac J; Palumbo-Zerr K; Ruzehaji N; Tomcik M; Zerr P; Dees C; Distler A; Beyer C; Schneider H; Distler O; Schett G; Allanore Y; Distler JH
    Arthritis Rheumatol; 2014 Nov; 66(11):3140-50. PubMed ID: 25155144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased expression of aquaporin-1 in dermal fibroblasts and dermal microvascular endothelial cells possibly contributes to skin fibrosis and edema in patients with systemic sclerosis.
    Yamashita T; Asano Y; Saigusa R; Taniguchi T; Nakamura K; Miura S; Toyama T; Takahashi T; Ichimura Y; Hirabayashi M; Yoshizaki A; Miyagaki T; Sugaya M; Sato S
    J Dermatol Sci; 2019 Jan; 93(1):24-32. PubMed ID: 30270117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of phosphodiesterase 4 (PDE4) reduces dermal fibrosis by interfering with the release of interleukin-6 from M2 macrophages.
    Maier C; Ramming A; Bergmann C; Weinkam R; Kittan N; Schett G; Distler JHW; Beyer C
    Ann Rheum Dis; 2017 Jun; 76(6):1133-1141. PubMed ID: 28209630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon regulatory factor 7 (IRF7) represents a link between inflammation and fibrosis in the pathogenesis of systemic sclerosis.
    Wu M; Skaug B; Bi X; Mills T; Salazar G; Zhou X; Reveille J; Agarwal SK; Blackburn MR; Mayes MD; Assassi S
    Ann Rheum Dis; 2019 Nov; 78(11):1583-1591. PubMed ID: 31439591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A Uuifying hypothesis for the pathogenesis of systemic sclerosis based on the deficiency of transcription factor Fli1 - the development of a new animal model of systemic sclerosis -].
    Asano Y
    Nihon Rinsho Meneki Gakkai Kaishi; 2014; 37(6):475-87. PubMed ID: 25748132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fli1-haploinsufficient dermal fibroblasts promote skin-localized transdifferentiation of Th2-like regulatory T cells.
    Saigusa R; Asano Y; Taniguchi T; Hirabayashi M; Nakamura K; Miura S; Yamashita T; Takahashi T; Ichimura Y; Toyama T; Yoshizaki A; Trojanowska M; Sato S
    Arthritis Res Ther; 2018 Feb; 20(1):23. PubMed ID: 29415756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of the Progression of Skin Inflammation, Fibrosis, and Vascular Injury by Blockade of the CX
    Luong VH; Utsunomiya A; Chino T; Doanh LH; Matsushita T; Obara T; Kuboi Y; Ishii N; Machinaga A; Ogasawara H; Ikeda W; Kawano T; Imai T; Oyama N; Hasegawa M
    Arthritis Rheumatol; 2019 Nov; 71(11):1923-1934. PubMed ID: 31173491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dersimelagon, a novel oral melanocortin 1 receptor agonist, demonstrates disease-modifying effects in preclinical models of systemic sclerosis.
    Kondo M; Suzuki T; Kawano Y; Kojima S; Miyashiro M; Matsumoto A; Kania G; Błyszczuk P; Ross RL; Mulipa P; Del Galdo F; Zhang Y; Distler JHW
    Arthritis Res Ther; 2022 Sep; 24(1):210. PubMed ID: 36050717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fli1 Deficiency Induces CXCL6 Expression in Dermal Fibroblasts and Endothelial Cells, Contributing to the Development of Fibrosis and Vasculopathy in Systemic Sclerosis.
    Taniguchi T; Asano Y; Nakamura K; Yamashita T; Saigusa R; Ichimura Y; Takahashi T; Toyama T; Yoshizaki A; Sato S
    J Rheumatol; 2017 Aug; 44(8):1198-1205. PubMed ID: 28507181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blockade of CCL24 with a monoclonal antibody ameliorates experimental dermal and pulmonary fibrosis.
    Mor A; Segal Salto M; Katav A; Barashi N; Edelshtein V; Manetti M; Levi Y; George J; Matucci-Cerinic M
    Ann Rheum Dis; 2019 Sep; 78(9):1260-1268. PubMed ID: 31129606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dipeptidylpeptidase 4 as a Marker of Activated Fibroblasts and a Potential Target for the Treatment of Fibrosis in Systemic Sclerosis.
    Soare A; Györfi HA; Matei AE; Dees C; Rauber S; Wohlfahrt T; Chen CW; Ludolph I; Horch RE; Bäuerle T; von Hörsten S; Mihai C; Distler O; Ramming A; Schett G; Distler JHW
    Arthritis Rheumatol; 2020 Jan; 72(1):137-149. PubMed ID: 31350829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.